We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FibroGen Initiates Phase II/III Study in Severe Coronavirus
Read MoreHide Full Article
FibroGen Inc. (FGEN - Free Report) announced that it has initiated a phase II/III open-label, study (BOREA) in Italy investigating the efficacy and safety of pamrevlumab in patients with severe COVID-19 infection. The study will include 68 hospitalized patients who will receive either pamrevlumab or standard of care. The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection.
Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders. CTGF may promote vascular leakage and lead to pulmonary edema or excess fluid in the lungs. Administration of pamrevlumab, an anti-CTGF monoclonal antibody, may reverse this edema, and thus improve oxygenation in patients with COVID-19-induced pneumonia.
This study will evaluate pamrevlumab’s effect on patient time to and on ventilatory support, and its potential to reduce mortality and fibrotic sequelae in the lung, a complication in COVID-19 patient
Shares of FibroGen have lost 21.7% year to date compared with the industry’s decline of 4%.
Further, FibroGen announced that it will initiate two additional phase II studies investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe COVID-19 infection in the United States. The Investigational New Drug (IND) application for the first study is approved by the FDA, and the study will assess the efficacy and safety of pamrevlumab in approximately 130 patients hospitalized with COVID-19 in the acute setting.
The second planned U.S. study, in discussions with the FDA, is expected to assess the longer term efficacy and safety of pamrevlumab in patients who recovered or are recovering from COVID-19 infection with evidence of interstitial lung disease.
The entire world is hoping for a rapid development of a treatment/antibody to treat COVID-19 or a vaccine to prevent the disease.
Meanwhile, several marketed drugs like Sanofi,/Regeneron’s IL-6 inhibitor Kevzara, Roche’s (RHHBY - Free Report) IL-6 inhibitor, Actemra, Incyte/Novarts’ JAK1/JAK2 inhibitor, Jakafi, AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence, Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla among others are being evaluated to treat respiratory complications associated with COVID-19, which is also the need of the hour.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
FibroGen Initiates Phase II/III Study in Severe Coronavirus
FibroGen Inc. (FGEN - Free Report) announced that it has initiated a phase II/III open-label, study (BOREA) in Italy investigating the efficacy and safety of pamrevlumab in patients with severe COVID-19 infection. The study will include 68 hospitalized patients who will receive either pamrevlumab or standard of care. The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection.
Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders. CTGF may promote vascular leakage and lead to pulmonary edema or excess fluid in the lungs. Administration of pamrevlumab, an anti-CTGF monoclonal antibody, may reverse this edema, and thus improve oxygenation in patients with COVID-19-induced pneumonia.
This study will evaluate pamrevlumab’s effect on patient time to and on ventilatory support, and its potential to reduce mortality and fibrotic sequelae in the lung, a complication in COVID-19 patient
Shares of FibroGen have lost 21.7% year to date compared with the industry’s decline of 4%.
Further, FibroGen announced that it will initiate two additional phase II studies investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe COVID-19 infection in the United States. The Investigational New Drug (IND) application for the first study is approved by the FDA, and the study will assess the efficacy and safety of pamrevlumab in approximately 130 patients hospitalized with COVID-19 in the acute setting.
The second planned U.S. study, in discussions with the FDA, is expected to assess the longer term efficacy and safety of pamrevlumab in patients who recovered or are recovering from COVID-19 infection with evidence of interstitial lung disease.
The entire world is hoping for a rapid development of a treatment/antibody to treat COVID-19 or a vaccine to prevent the disease.
Meanwhile, several marketed drugs like Sanofi,/Regeneron’s IL-6 inhibitor Kevzara, Roche’s (RHHBY - Free Report) IL-6 inhibitor, Actemra, Incyte/Novarts’ JAK1/JAK2 inhibitor, Jakafi, AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence, Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla among others are being evaluated to treat respiratory complications associated with COVID-19, which is also the need of the hour.
FibroGen, Inc Price
FibroGen, Inc price | FibroGen, Inc Quote
Zacks Rank
FibroGen currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>